<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01298960</url>
  </required_header>
  <id_info>
    <org_study_id>FUNDEX001</org_study_id>
    <secondary_id>2010-022151-32</secondary_id>
    <nct_id>NCT01298960</nct_id>
  </id_info>
  <brief_title>Growth Hormone (GH) in in Vitro Fertilization (IVF) Poor-responder Patients</brief_title>
  <acronym>FUNDEX001</acronym>
  <official_title>Phase II Randomized Study of Cotreatment With Growth Hormone in a Long GnRH Agonist Protocol in Women With Previous Poor Ovarian Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Universitari Dexeus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Universitari Dexeus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Experimental study to evaluate if rGH addition to a standard controlled ovarian stimulation
      treatment improves ovarian response in women with previous poor ovarian response.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <start_date>February 2011</start_date>
  <completion_date>June 2013</completion_date>
  <primary_completion_date>June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of metaphase II oocytes retrieved</measure>
    <time_frame>3 months after having finished recruitment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pregnancy rate</measure>
    <time_frame>9 months after ovum pick-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events due to rGH</measure>
    <time_frame>3 months after having finished recruitment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Complications; Artificial Fertilization, Introduction of Embryo in Embryo Transfer</condition>
  <arm_group>
    <arm_group_label>rGH Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Non rGH group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Somatropin</intervention_name>
    <description>0.1 IU/Kg/day from day one of stimulation until rHCG triggering</description>
    <arm_group_label>rGH Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women who desire pregnancy with regular spontaneous menstrual cycles of 25-30 days
             length.

          -  Infertility requiring IVF with or without ICSI.

          -  Antecedent of a failed previous IVF cycle with a GnRH long agonist protocol in which
             at least 3000 IU of FSH were used (cancellation due to poor ovarian response - &lt; 4
             mature follicles - or less than 5 oocytes retrieved)and antral follicle count &lt; 5.

          -  Partner sperm.

          -  Presence of both ovaries and normal uterine cavity.

          -  PAP smear within normality in previous 3 years.

          -  Negative pregnancy test (serum or urine) before rFSH administration.

          -  Willingness of adhesion to protocol during the whole study period.

          -  Signed informed consent given.

        Exclusion Criteria:

          -  HIV, HCV, HBV positive serologies in women or partner.

          -  Important systemic diseases that could interfere with gonadotrophin treatment (ovarian
             and hypothalamic tumors...).

          -  BMI &gt; 32 kg/m2 or antecedent of diabetes mellitus.

          -  Gonadotrophin treatment within the previous 30 days.

          -  Availability of frozen embryos of previous IVF cycles .

          -  Abnormal uterine bleeding.

          -  Previous treatment with LH or LH effect drugs.

          -  Polycystic ovaries, increased size ovaries or presence of ovarian cysts of unknown
             ethiology.

          -  Contraindication for pregnancy.

          -  Allergies to gonadotrophins or somatotropin.

          -  History of drug or alcohol abuse in the previous 5 years.

          -  Previous enrollment in this study or simultaneous participation in another study with
             drugs.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro N Barri, PhD, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Obstetrics, Gyneacology and Reproductive Medicine, Institut Universitari Dexeus</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Buenaventura Coroleu, PhD. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Departament of Obstetrics, Gyneacology and Reproductive Medine, Institut Universitari Dexeus</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marta Devesa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Obstetrics, Gyneacology and Reproductive Medicine, Institut Universitari Dexeus</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francisca Martinez, PhD. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Obstetrics, Gyneacology and Reproductive Medicine, Institut Universitari Dexeus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Departamento de Obstetricia Ginecologia y Reproducci√≥n. Institut Universitari Dexeus</name>
      <address>
        <city>Barcelona</city>
        <zip>08037</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.dexeus.com</url>
  </link>
  <reference>
    <citation>Harper K, Proctor M, Hughes E. Growth hormone for in vitro fertilization. Cochrane Database Syst Rev. 2003;(3):CD000099. Review. Update in: Cochrane Database Syst Rev. 2009;(4):CD000099.</citation>
    <PMID>12917883</PMID>
  </reference>
  <reference>
    <citation>Kolibianakis EM, Venetis CA, Diedrich K, Tarlatzis BC, Griesinger G. Addition of growth hormone to gonadotrophins in ovarian stimulation of poor responders treated by in-vitro fertilization: a systematic review and meta-analysis. Hum Reprod Update. 2009 Nov-Dec;15(6):613-22. doi: 10.1093/humupd/dmp026. Epub 2009 Jun 26. Review.</citation>
    <PMID>19561136</PMID>
  </reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2011</study_first_submitted>
  <study_first_submitted_qc>February 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2011</study_first_posted>
  <last_update_submitted>June 30, 2015</last_update_submitted>
  <last_update_submitted_qc>June 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institut Universitari Dexeus</investigator_affiliation>
    <investigator_full_name>Ignacio Rodriguez</investigator_full_name>
    <investigator_title>BSC</investigator_title>
  </responsible_party>
  <keyword>Poor Ovarian response in IVF</keyword>
  <keyword>Metaphase II oocytes</keyword>
  <keyword>Pregnancy Rate</keyword>
  <keyword>Growth Hormone</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

